Keyword: Juno Therapeutics
Gregory Verdine’s FogPharma raised $66 million in series B financing, with hopes to bring its first product to the clinic by the end of next year.
A CAR-T biotech formed by Juno and WuXi got off a $90 million series A with Chinese backing, as it eyes clinical trials of its new cancer therapy.
We started the Rotten Tomatoes special feature last year to spotlight companies that haven't followed through on the tough ethical and scientific demands of the biotech industry. This year, we’re at it again with a bit of a twist: We included companies bruised in 2016 but revived in 2017.
Kite will use the ZFN gene editing platform to create next-generation, off-the-shelf CAR-T therapies to cement its position in the cell therapy space.
Celgene agreed to buy CAR-T specialist Juno Therapeutics for around $9 billion in a deal instantly making it a big cheese in therapeutics.
Celgene is lining up another deal for CAR-T biotech Juno Therapeutics, according to several media reports.
Novartis poached Pfizer oncology head Liz Barrett, Ed Kaye became Stoke Therapeutics' CEO, and Perrigo hired Uwe Röhrhoff as CEO.
Johnson & Johnson is paying $350 million upfront to join forces with Legend as they look for a working “cure” for certain blood cancers.
Juno Therapeutics, which dumped its lead CAR-T program in March, has inked license agreements with Eli Lilly, OncoTracker and Fred Hutch.